Please login to the form below
cancer
This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.
Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
In February, Janssen revealed additional results for Erleada, this time in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ... In the EU, Erleada is approved for the treatment of
Latest news
-
In sickness and in health
see patient versions of Abbott’s i-STAT device. Out of the home, innovations like Philip’s Ingenia are enabling early cancer detection by integrating MRI and CT scans, which of
-
GSK discontinues two feladilimab trials in head and neck cancer
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
most common form of kidney cancer. ... now with a new immunotherapy and tyrosine kinase inhibitor regimen,” said Dana Walker, vice president, development programme lead, genitourinary cancers, BMS.
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .
-
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
including pancreatic, colon, breast and salivary cancer, with 62.5% having gastrointestinal tumours. ... These findings further demonstrate the importance of broad tumour profiling in advanced cancers,” he added.
More from news
Approximately 715 fully matching, plus 3,150 partially matching documents found.
Latest Intelligence
-
Virtual congresses: video thrilled the cardio tsar
Its application to major congresses across all medical disciplines – from cancer to cardiovascular, respiratory to rheumatology – will undoubtedly continue.
-
Mapping the patient journey: eight ways to improve support programmes
In some areas, such as gene therapies and high-cost cancer treatments, accelerated approval and early access schemes are conditional on capturing real-world outcomes data – and patient support tools provide
-
Building meaningful customer engagement through data-driven digital insights
Pancreatic Cancer. HCPs shared, mentioned and interacted with these groups, reflecting the trust that exists between them. ... has been a key driver of the online HCP conversation around pancreatic cancer.
-
Reaching patients and HCPs during the pandemic
When UroGen received FDA approval for Jelmyto (mitomycin gel) in April 2020, the drug became the first therapy approved to treat low-grade upper tract urothelial cancer (UTUC).
-
The promise of precision medicine
The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced non-small-cell lung cancer by four to five
More from intelligence
Approximately 8 fully matching, plus 339 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients,” he added.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
McCann Health France strengthens team with two new hires
Prior to McCann Health France, she served as scientific director at various international health organisations, including the ARC Foundation for Cancer Research and the French National Cancer Institute.
-
Genmab hires first chief operating officer
Anthony shares our determination to bring truly differentiated new cancer treatments to the market that will deliver on our commitment to improve patients’ lives while fostering a culture of excellence and
-
New hires at Crescendo, Healx and Galecto
Galecto. Galecto, a clinical stage company developing treatments for fibrosis and cancer, has appointed Bertil Lindmark as its new chief medical officer.
More from appointments
Approximately 5 fully matching, plus 209 partially matching documents found.
Latest from PMHub
-
Abbie's (associate copywriter) first 6-months at COUCH Health
I covered biological mechanisms of how chemotherapy works, what cancer actually is, and different mechanisms of detecting cancer in the blood.
-
WHITE PAPER: Why do men die younger?
5. Many of the most common health conditions affecting men including coronary heart disease, diabetes and various cancers are also known to be affected by these habits. ... 10. This includes:. Supporting research efforts for male-specific diseases such
-
Mednet Group’s growth spurt
in cancer biology and she has experience working as a research technician in the field of malignant haematology. .
-
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
3. The Eve Appeal, a charity for gynaecological cancers, found in a survey of healthcare professionals that 47% agreed that women not knowing the correct terminology for their reproductive anatomy could ... Women are unnecessarily dying in childbirth or
-
Is social media for clinical trial recruitment justified?
Well, not necessarily. According to a survey study from late December, 78% of the 92 surveyed participants had never used social media as a patient recruitment method for cancer clinical trials.
More from PMHub
Approximately 43 fully matching, plus 207 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Associate Account Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Content Editor - Biotechnology
-
Salary TBC
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- GSK discontinues two feladilimab trials in head and neck cancer
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine
- Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
- Health leaders welcome EDPB’s opinion on adequacy of UK’s data protection standards
- bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
- Havas Health & You appoints Pat Thistlethwaite as chief experience officer
- Empowering patients empowers results
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Empowering patients empowers results
- Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
- Don’t limit diversity to just representation in clinical trials
- What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
- Oh no… not more training
- Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
Quick links
Infographics
